

contributed to the initial hypomanic episode. Clinicians should be aware of this potential interaction and closely monitor valproic acid concentrations and efficacy. A valproic acid dose increase may be needed. In addition, valproic acid is an inducer of P-glycoprotein (P-gp) and an inhibitor/inducer of CYP3A4; ritonavir is a substrate of both CYP3A4 and P-gp.

● **Level 3 (Moderate)** (no results)

● **Level 4 (Minor)** (no results)

---

**Copyright © 2017 Elsevier / Gold Standard. All rights reserved.**